Abstract Details

Title Safety, Tolerability and Pharmacokinetics of Crenezumab in Mild-to-Moderate AD Patients Treated with Escalating Doses for up to 32.3 Months

Topic Aging and Dementia

Presentation(s) P6 - (-)

Poster/Presentation
Number 182

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Helen C. Lin, MD PRESENTER	Dr. Lin has received personal compensation for serving as an employee of Genentech. Dr. Lin has stock in Genentech.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jillian Smith	Jillian Smith has received personal compensation for serving as an employee of Roche Products Ltd. Jillian Smith has stock in Roche Holdings. Jillian Smith has received intellectual property interests from a discovery or technology relating to health care.
William Cho	No disclosure on file
Susanne Ostrowitzki, MD, PhD	No disclosure on file

��ɫ��